Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study)
Authors' conclusion
Once-weekly semaglutide administration improved glycaemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite glucagon-like receptor-1 receptor agonist treatment.
Study context
- Population
- Patients with T2D treated with liraglutide 0.9–1.8 mg/day or dulaglutide 0.75 mg/week; 37 completed plan A and 63 plan B10 excluded
- Participants
- 110 patients
- Comparison
- Switch to once-weekly semaglutide vs continuing liraglutide (plan A) or dulaglutide (plan B)
- Primary endpoint
- Mean change in HbA1c
- Follow-up
- 24 weeks
Methodological detailsmulticentre, open-label, prospective, parallel-group
- Multicentre
- Open-label
- Prospective
- Parallel-group
Primary result
As reported in the abstract
HbA1c
Semaglutide (plan A) vs Liraglutide: P < 0.01 · Semaglutide (plan B) vs Dulaglutide: P < 0.01
Secondary outcomes
| Outcome | Liraglutide | Semaglutide (plan A) | Dulaglutide | Semaglutide (plan B) |
|---|---|---|---|---|
| HbA1c at baseline | 7.8% ± 1.0% | 7.9% ± 0.7% | 7.8% ± 1.0% | 7.8% ± 0.8% |
- Diabetes Treatment Satisfaction Questionnaire score change · Semaglutide (plan A) vs Liraglutide · improved with semaglutide
- P < 0.01
- Diabetes Treatment Satisfaction Questionnaire score change · Semaglutide (plan B) vs Dulaglutide · improved with semaglutide
- P < 0.01
Diabetes Treatment Satisfaction Questionnaire score change
- Semaglutide improved treatment satisfaction scores in both plans
Body weight and metabolic parameters
- Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters
Original publication
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study). Diabetes Obes Metab. Published 28 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →